Verastem, Inc. (0LOV.L)
USD 5.58
(25.11%)
USD 5.58
(25.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 92.08 Million USD | 21.83% |
| 2022 | 75.53 Million USD | 19.02% |
| 2021 | 63.46 Million USD | -39.06% |
| 2020 | 104.13 Million USD | -29.16% |
| 2019 | 146.99 Million USD | 21.14% |
| 2018 | 121.33 Million USD | 78.95% |
| 2017 | 67.8 Million USD | 83.24% |
| 2016 | 37 Million USD | -36.42% |
| 2015 | 58.19 Million USD | 8.57% |
| 2014 | 53.6 Million USD | 29.48% |
| 2013 | 41.4 Million USD | 28.46% |
| 2012 | 32.23 Million USD | 135.29% |
| 2011 | 13.69 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 28.05 Million USD | -9.9% |
| 2024 Q2 | 28.27 Million USD | 0.78% |
| 2023 FY | 92.02 Million USD | 21.83% |
| 2023 Q3 | 21.3 Million USD | 5.01% |
| 2023 Q4 | 31.13 Million USD | 46.11% |
| 2023 Q2 | 20.29 Million USD | 4.9% |
| 2023 Q1 | 19.34 Million USD | 14.83% |
| 2022 Q1 | 19.57 Million USD | 14.77% |
| 2022 FY | 75.53 Million USD | 19.02% |
| 2022 Q4 | 16.84 Million USD | -4.87% |
| 2022 Q3 | 17.7 Million USD | -17.26% |
| 2022 Q2 | 21.4 Million USD | 9.33% |
| 2021 Q4 | 17.05 Million USD | 14.87% |
| 2021 Q3 | 14.84 Million USD | -9.71% |
| 2021 Q2 | 16.44 Million USD | 8.8% |
| 2021 Q1 | 15.11 Million USD | -12.37% |
| 2021 FY | 63.46 Million USD | -39.06% |
| 2020 Q3 | 31.56 Million USD | 27.37% |
| 2020 FY | 104.13 Million USD | -29.16% |
| 2020 Q1 | 30.52 Million USD | -15.63% |
| 2020 Q2 | 24.78 Million USD | -18.81% |
| 2020 Q4 | 17.24 Million USD | -45.36% |
| 2019 FY | 146.99 Million USD | 21.14% |
| 2019 Q4 | 36.18 Million USD | 5.27% |
| 2019 Q3 | 34.37 Million USD | -15.43% |
| 2019 Q2 | 40.64 Million USD | 12.33% |
| 2019 Q1 | 36.18 Million USD | 2.35% |
| 2018 Q3 | 37.02 Million USD | 31.33% |
| 2018 Q4 | 35.35 Million USD | -4.52% |
| 2018 Q2 | 28.19 Million USD | 35.8% |
| 2018 Q1 | 20.76 Million USD | 15.01% |
| 2018 FY | 121.33 Million USD | 78.95% |
| 2017 FY | 67.8 Million USD | 83.24% |
| 2017 Q1 | 13.14 Million USD | 11.42% |
| 2017 Q4 | 18.05 Million USD | -21.98% |
| 2017 Q3 | 23.13 Million USD | 71.81% |
| 2017 Q2 | 13.46 Million USD | 2.43% |
| 2016 Q2 | 8.7 Million USD | 3.26% |
| 2016 Q3 | 8.05 Million USD | -7.46% |
| 2016 Q1 | 8.43 Million USD | -29.49% |
| 2016 FY | 37 Million USD | -36.42% |
| 2016 Q4 | 11.8 Million USD | 46.42% |
| 2015 FY | 58.19 Million USD | 8.57% |
| 2015 Q4 | 11.96 Million USD | -23.0% |
| 2015 Q3 | 15.53 Million USD | 0.47% |
| 2015 Q2 | 15.46 Million USD | 1.44% |
| 2015 Q1 | 15.24 Million USD | 8.89% |
| 2014 FY | 53.6 Million USD | 29.48% |
| 2014 Q3 | 13.38 Million USD | 2.3% |
| 2014 Q2 | 13.08 Million USD | -0.36% |
| 2014 Q1 | 13.13 Million USD | 15.28% |
| 2014 Q4 | 13.99 Million USD | 4.56% |
| 2013 FY | 41.4 Million USD | 28.46% |
| 2013 Q1 | 9.08 Million USD | 13.85% |
| 2013 Q2 | 10.28 Million USD | 13.25% |
| 2013 Q3 | 10.64 Million USD | 3.5% |
| 2013 Q4 | 11.39 Million USD | 7.04% |
| 2012 Q2 | 6.89 Million USD | -0.46% |
| 2012 FY | 32.23 Million USD | 135.29% |
| 2012 Q1 | 6.92 Million USD | 15.08% |
| 2012 Q3 | 10.43 Million USD | 51.25% |
| 2012 Q4 | 7.97 Million USD | -23.53% |
| 2011 Q4 | 6.02 Million USD | 48.75% |
| 2011 Q3 | 4.04 Million USD | 62.86% |
| 2011 Q2 | 2.48 Million USD | 116.84% |
| 2011 Q1 | 1.14 Million USD | 0.0% |
| 2011 FY | 13.69 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 67.7% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -89.856% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -658.455% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 95.646% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 77.475% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 94.884% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 78.467% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -65.155% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 66.599% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 80.669% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 94.727% |
| bluebird bio, Inc. | 240.23 Million USD | 61.669% |
| Blueprint Medicines Corporation | 722.86 Million USD | 87.261% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 35.363% |
| Imunon, Inc. | 21.03 Million USD | -337.861% |
| Adicet Bio, Inc. | 152.03 Million USD | 39.434% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 75.019% |
| Dynavax Technologies Corporation | 219.14 Million USD | 57.98% |
| Editas Medicine, Inc. | 247.3 Million USD | 62.765% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 91.18% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 66.133% |
| Exelixis, Inc. | 1.58 Billion USD | 94.197% |
| FibroGen, Inc. | 398.11 Million USD | 76.87% |
| Geron Corporation | 70.44 Million USD | -30.725% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 69.235% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 23.681% |
| Illumina, Inc. | 3.81 Billion USD | 97.585% |
| Incyte Corporation | 1.19 Billion USD | 92.265% |
| Insmed Incorporated | 949.26 Million USD | 90.299% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 83.305% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 88.188% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 79.582% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 95.515% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -135.19% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 91.547% |
| Evolus, Inc. | 189.75 Million USD | 51.473% |
| Myriad Genetics, Inc. | 600.1 Million USD | 84.655% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 94.232% |
| OPKO Health, Inc. | 574.68 Million USD | 83.977% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 93.233% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 82.593% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.773% |
| Waters Corporation | 943.51 Million USD | 90.24% |
| Zoetis Inc. | 2.76 Billion USD | 96.67% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.072% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.102% |
| Biogen Inc. | 5.2 Billion USD | 98.231% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 59.732% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 96.729% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -562.016% |
| Homology Medicines, Inc. | 9.87 Million USD | -832.496% |
| Nektar Therapeutics | 190.9 Million USD | 51.764% |
| TG Therapeutics, Inc. | 198.47 Million USD | 53.604% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 8.671% |
| Perrigo Company plc | 1.52 Billion USD | 93.976% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -106.157% |